Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 19, 2026
Why Is Merck & Co., Inc. (MRK) Stock Up +13.04% Today?

Why Is Merck & Co., Inc. (MRK) Stock Up +13.04% Today?

Key Takeaways

  • Merck & Co., Inc. (MRK) surged roughly 13% on Wednesday, climbing from a prior close of $135.17 to about $152.80.
  • The primary catalyst was a landmark Phase 3 win for the company's personalized mRNA cancer therapy, developed with Moderna.
  • The combination of intismeran autogene and Keytruda met both recurrence-free survival and distant metastasis-free survival endpoints in high-risk melanoma.
  • The move extended Keytruda's growth runway as the blockbuster drug approaches patent expiration later this decade.
  • Trading volume ran well above average, and partner MRNA (Moderna) posted an even larger gain on the same news.
  • Investors are now watching for full data, regulatory discussions, and readouts from the broader INTerpath trial program.

Opening Summary

Shares of Merck & Co., Inc. (MRK), the Rahway, New Jersey-based pharmaceutical giant best known for its blockbuster immunotherapy Keytruda, climbed sharply on Wednesday after the company and partner Moderna reported positive late-stage results for their experimental personalized cancer vaccine. The stock traded up about 13%, rising from a prior session close of $135.17 to roughly $152.80. The rally marked one of the stock's strongest single-session moves in years and was driven squarely by clinical data that Wall Street views as a potential new growth engine for Merck's oncology franchise.

Landmark Phase 3 Cancer Vaccine Results

The catalyst was clear. Merck and Moderna announced that the Phase 3 INTerpath-001 trial met its primary and key secondary endpoints, marking the first positive Phase 3 result ever for an mRNA-based cancer therapy. The study evaluated intismeran autogene — a personalized, mRNA-based individualized neoantigen therapy — in combination with Keytruda, versus Keytruda alone, in more than 1,100 patients with surgically removed, high-risk stage IIB-IV melanoma.

The combination produced statistically significant and clinically meaningful improvements in recurrence-free survival and distant metastasis-free survival, with no new safety signals. Because Keytruda is already the standard of care in this setting, a regimen that beats Keytruda monotherapy represents a meaningful scientific and commercial milestone.

What It Means for Keytruda's Franchise

The readout matters strategically for MRK because Keytruda is the company's dominant revenue engine — generating tens of billions of dollars annually — and faces patent expiration later this decade. A successful personalized cancer vaccine paired with Keytruda could deepen and extend that franchise, giving Merck a new growth layer built around its most important asset.

The data also validates the broader promise of the INTerpath clinical program, which spans multiple tumor types including lung, bladder, and kidney cancer. A positive readout in additional indications would significantly expand the therapy's addressable market.

Market Context and Trading Activity

The rally came on elevated trading volume, reflecting broad institutional and retail participation in the stock. Options activity also surged, with call volume running well above average as traders positioned for continued upside. The move was reinforced by strong sector sympathy: Moderna (MRNA) soared more than 100% on the same announcement, and other mRNA-focused names rose in sympathy.

The gain pushed MRK toward multi-year and record highs, decisively clearing recent resistance levels. The strength was company-specific rather than a broad-market move, underscoring that the advance was fundamentally a reaction to the clinical data rather than a general risk-on shift.

What Comes Next for MRK

Looking ahead, investors will focus on several key items. Merck and Moderna plan to present full trial data at an upcoming medical meeting and engage with regulators about potential filing pathways. The magnitude and durability of the survival benefit, once disclosed in detail, will be closely scrutinized.

Secondary endpoints, including overall survival, remain under evaluation as the trial continues. Results from the broader INTerpath program — particularly in lung cancer — represent the next major catalysts, alongside Merck's quarterly earnings and commentary on Keytruda's patent cliff strategy. Risks include regulatory hurdles, the complexity and cost of manufacturing a personalized therapy, and the possibility that subsequent trial readouts fail to replicate this success.

Trending AI Robots

Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, but only the strongest performers under current market conditions are showcased in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of approaches to explore. For those looking to complement their own research with AI-driven signals, reviewing the Trending AI Robots list can be a useful starting point.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MRK

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


MRK's RSI Oscillator recovers from overbought zone

The 10-day RSI Oscillator for MRK moved out of overbought territory on August 27, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 instances where the indicator moved out of the overbought zone. In 19 of the 35 cases the stock moved lower in the days that followed. This puts the odds of a move down at 54%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRK as a result. In 40 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 48%.

The Moving Average Convergence Divergence Histogram (MACD) for MRK turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 24 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 47%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.

MRK broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 37 of 53 cases where MRK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.

Following a +2.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 200 of 345 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.

The Aroon Indicator entered an Uptrend today. In 165 of 260 cases where MRK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.643) is normal, around the industry mean (19.050). MRK's P/E Ratio (117.496) is considerably higher than the industry average of (34.258). Projected Growth (PEG Ratio) (2.683) is also within normal values, averaging (5.614). Dividend Yield (0.023) settles around the average of (0.025) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).

The Tickeron Profit vs. Risk Rating rating for this company is 32 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 197.52B. The market cap for tickers in the group ranges from 4.8K to 1.03T. LLY holds the highest valuation in this group at 1.03T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 2%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 15%. MIRA experienced the highest price growth at 8%, while GRFS experienced the biggest fall at -3%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 178%. For the same stocks of the Industry, the average monthly volume growth was 32% and the average quarterly volume growth was -23%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 26
P/E Growth Rating: 55
Price Growth Rating: 52
SMR Rating: 59
Profit Risk Rating: 63
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
MRK
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of human and animal health products

Industry PharmaceuticalsMajor

Profile
Details
Industry
Pharmaceuticals Major
Address
126 East Lincoln Avenue
Phone
+1 908 740-4000
Employees
75000
Web
https://www.merck.com
Interact to see
Advertisement
VIA fell over 11% today, extending a slide that began last week; the stock has been under pressure since trading around the high‑teens and low‑$20s, well below its $46 IPO price.
LAES fell more than 19% today as the market digested a $125 million registered direct offering of 30.4 million new shares (or pre‑funded warrants) plus warrants for up to 60.8 million additional shares, all priced at $4.11 per unit.
Shares of ALDX are down about 73.02% in premarket trading, plunging from a prior close near 4.13 dollars to roughly 1.11 dollars after a major regulatory setback. The collapse follows fresh confirmation that the U.S. Food and Drug Administration has again declined to approve reproxalap for dry eye disease, issuing another Complete Response Letter that questions efficacy.
Shares of MVST are down about 25% in premarket trading today compared with the prior close. The slide follows a sharp reassessment of the company’s outlook as investors react to new information and recent volatility in high‑beta battery and EV names.
Solaris Energy Infrastructure’s stock SEI jumped roughly 13% in today’s session, extending a sharp recent rebound from early-March lows. The move is driven by ongoing post-earnings momentum after strong Q4 and full‑year 2025 results and raised guidance highlighted rapid growth in its power solutions business.
Shares of LMND are trading approximately +10% higher intraday on Tuesday, March 17, 2026, rising from a prior close of $57.74 to around $63.51. Primary catalyst: Morgan Stanley upgraded LMND to an 'Overweight' rating and raised its price target to $85 from $80.
Shares of ICHR surged approximately +15% intraday on Tuesday, March 17, 2026, trading near $48.98 versus a prior closing price of $42.59. The primary catalyst is a high-profile analyst upgrade by Stifel, with analyst Brian Chin upgrading the stock to Buy citing improved cyclical strength and conviction in the company's revenue and margin trajectory.
NBIS shares are down approximately 10.00% in Tuesday's session, falling from a prior close of $129.85 to around $116.87. The primary catalyst is Nebius Group's pre-market announcement of a proposed $3.75 billion convertible senior notes offering, sparking dilution concerns.
TME shares fell over 20% today, with the stock sliding from the mid‑$15s toward the low‑$13s in the wake of its Q4 2025 report and earnings call, extending a pre‑market drop of roughly 12–13%.
HUYA shares fell over 11% today, dropping from the mid‑$3 range toward the low‑$3s following the company’s Q4 2025 earnings release before the U.S. market open. Q4 total net revenues rose about 16% year over year to roughly CNY 1.74 billion, with full‑year 2025 revenues up around 7% to CNY 6.5 billion, but the market had already priced in a rebound after a difficult 2024.​
CWCO fell over 9% today, trading around the low‑$31 range versus recent levels in the mid‑$30s to near $39, as the market reacted negatively to Q4 2025 results and forward commentary. Full‑year 2025 results showed stable earnings and dividend growth but a roughly 9% decline in services revenue to about $46.3 million, reflecting a slowdown in project‑based construction work.
SMTC shares dropped over 8% today after the company reported Q4 results that met or modestly beat Street estimates but showed the slowest year‑over‑year revenue growth in several quarters, at about 9.3% to roughly $274–275 million.
AXTI shares slipped more than 6% today, reversing part of a powerful rally that had recently driven the stock to a 52‑week high above $47 and more than doubled its price year‑to‑date. Q4 2025 revenue of about $23.0 million missed consensus by roughly $1.2 million and fell 8–18% year over year and sequentially, while the company posted another GAAP net loss of around $3.5 million (–$0.08 per share).
Shares of SailPoint, Inc. (SAIL) are tumbling approximately 12% in premarket trading on March 18, 2026, after the company released its fiscal fourth-quarter and full-year 2026 results before the market opened. While Q4 revenue came in slightly above consensus at $295 million (+23% year-over-year), investors were rattled by disappointing forward guidance for fiscal 2027.
Shares of KC surged approximately +17% in premarket trading on March 18, 2026, from a prior close of $13.12 to approximately $15.35. The primary catalyst is Kingsoft Cloud's release of its unaudited Q4 and full-year 2025 financial results before the U.S. market open, which appear to have significantly exceeded analyst expectations.
AngloGold Ashanti (AU) shares tumbled approximately 7% in premarket trading on March 18, 2026, extending a multi-week downtrend that has erased nearly 20% of the stock's value since late January highs. The primary catalyst driving the decline is persistent investor concern over AngloGold's lowered 2026 production guidance, with the company projecting gold output of 2.80–3.17 million ounces — a roughly 3% decline from its 2025 production of 3.1 million ounces.
AAOI shares surged approximately 10.90% in premarket trading on March 18, 2026, rising from a prior close of $86.33 to $95.74. The primary catalyst is strong positive sentiment generated at OFC 2026 — the Optical Fiber Communications Conference and Exhibition — where Applied Optoelectronics unveiled breakthrough laser and transceiver technology for next-generation AI data center infrastructure.
LITE shares surged approximately +12% in early Wednesday trading on March 18, 2026, with the stock changing hands near $727 compared to a prior session close of $649.56. The primary near-term catalyst is Lumentum's S&P 500 index inclusion, effective March 23, 2026, triggering front-running by institutional investors and mandatory buying by passive index funds.
Shares of New Era Energy & Digital, Inc. (NUAI) are trading down approximately 17% during today's session, with the prior close sitting at $5.56. The decline follows the company's March 17 business update conference call and webcast, held after market hours, during which management discussed the recently filed fiscal year 2025 annual report (Form 10-K).
Shares of Regencell Bioscience Holdings (RGC) are up approximately +16% intraday on March 18, 2026, trading at $26.56 against a prior close of $22.97. No single company-specific press release is driving today's move; the rally is primarily fueled by retail-driven momentum and short squeeze mechanics.